Itraconazole

Wilms Tumor

Samsung Medical CenterPhase 4 / ApprovedDormant

BB

67/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 53/ 100
Competitive Position: 89/ 100

Competitive context

40 Active assets in the Wilms Tumor cohort.

Asset / Sponsor	Phase	Rating
Inno-206 Children's National Research Institute	Phase 2	BB
(+)-VINCRISTINE Centre Oscar Lambret	Phase 2	BB
Irinotecan Centre Oscar Lambret	Phase 2	BB
Cyclophosphamide St. Jude Children's Research Hospital	Phase 2	BB
FILGRASTIM Barbara Ann Karmanos Cancer Institute	Phase 3	BB

View all 50 →

Same molecule, other indications

Itraconazole is also rated in:

retinoblastomaDormant

BB

Indicative ·

68 / 100

fungal infectious diseaseDormant

BB

Indicative ·

68 / 100

Androgen-insensitive Prostate CancerDormant

BB

Indicative ·

66 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.